SCRI, YCC, SCH announce collaboration
NASHVILLE, Tenn.—The Sarah Cannon Research Institute (SCRI) recently announced a scientific collaboration with the Yale Cancer Center (YCC) and the Smilow Cancer Hospital at Yale-New Haven (SCH) for the advancement of cancer research. A clinical trial management office on the YCC campus in New Haven, Conn., will be opened in conjunction with the agreement, and SCH will develop a network of community-based sites to participate in the program. SCRI and YCC scientists will partner to develop clinical research protocols, with SCRI providing assistance in opening research centers at Yale and supplementing clinical trial availability and patient participation in Yale's service area.
"This collaboration allows top scientific thought leaders in cancer to come together to develop enhanced clinical trial opportunities and increase access for patients to the latest treatments available," said Dr. Howard "Skip" A. Burris III, SCRI's chief medical officer and executive director of drug development.